HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.

AbstractOBJECTIVE:
High-sensitivity C-reactive protein (hsCRP) levels are closely associated with abdominal obesity, metabolic syndrome, and atherosclerotic cardiovascular disease. The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has encouraged using hsCRP ≥2 mg/L to guide statin therapy; however, the association of hsCRP and atherosclerosis, independent of obesity, remains unknown.
METHODS AND RESULTS:
We studied 6760 participants from the Multi-Ethnic Study of Atherosclerosis (MESA). Participants were stratified into 4 groups: nonobese/low hsCRP, nonobese/high hsCRP, obese/low hsCRP, and obese/high hsCRP. Using multivariable logistic and robust linear regression, we described the association with subclinical atherosclerosis, using coronary artery calcium (CAC) and carotid intima-media thickness (cIMT). Mean body mass index was 28.3±5.5 kg/m(2), and median hsCRP was 1.9 mg/L (0.84 to 4.26). High hsCRP, in the absence of obesity, was not associated with CAC and was mildly associated with cIMT. Obesity was strongly associated with CAC and cIMT independently of hsCRP. When obesity and high hsCRP were both present, there was no evidence of multiplicative interaction. Similar associations were seen among 2083 JUPITER-eligible individuals.
CONCLUSION:
High hsCRP, as defined by JUPITER, was not associated with CAC and was mildly associated with cIMT in the absence of obesity. In contrast, obesity was associated with both measures of subclinical atherosclerosis independently of hsCRP status.
AuthorsMichael J Blaha, Juan J Rivera, Matthew J Budoff, Ron Blankstein, Arthur Agatston, Daniel H O'Leary, Mary Cushman, Susan Lakoski, Michael H Criqui, Moyses Szklo, Roger S Blumenthal, Khurram Nasir
JournalArteriosclerosis, thrombosis, and vascular biology (Arterioscler Thromb Vasc Biol) Vol. 31 Issue 6 Pg. 1430-8 (Jun 2011) ISSN: 1524-4636 [Electronic] United States
PMID21474823 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium
  • C-Reactive Protein
  • Calcium
Topics
  • Adult
  • Aged
  • Atherosclerosis (blood, drug therapy, etiology)
  • Body Mass Index
  • C-Reactive Protein (analysis)
  • Calcium (blood)
  • Cardiovascular Diseases (etiology, prevention & control)
  • Carotid Arteries (pathology)
  • Clinical Trials as Topic
  • Cross-Sectional Studies
  • Female
  • Fluorobenzenes (therapeutic use)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Male
  • Metabolic Syndrome (blood)
  • Middle Aged
  • Obesity (blood, complications)
  • Pyrimidines (therapeutic use)
  • Rosuvastatin Calcium
  • Sulfonamides (therapeutic use)
  • Tunica Intima (pathology)
  • Tunica Media (pathology)
  • Waist Circumference

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: